The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -47,594 | -42,538 | -180,585 |
| Depreciation and amortization of property and equipment | 1,608 | 1,678 | 7,193 |
| Amortization of finance lease right of use asset | 538 | 539 | 1,615 |
| Impairment of operating lease right-of-use asset | - | 262 | - |
| Stock-based compensation | 8,493 | 6,112 | 30,947 |
| Accretion of discount on investments, net | 1,020 | 1,088 | 5,886 |
| Change in fair value of warrant liabilities | - | 0 | 0 |
| Prepaid expenses and other assets | 1,643 | -1,150 | -939 |
| Accounts payable and accrued expenses | -5,749 | -967 | -9,384 |
| Operating lease liabilities and right of use assets, net | -29 | 11 | 34 |
| Finance lease liability | 0 | 2 | 33 |
| Other liabilities | 2 | -1 | -80 |
| Net cash used in operating activities | -45,394 | -34,840 | -155,174 |
| Purchases of investments | 48,709 | 54,495 | 222,058 |
| Proceeds from maturities of investments | 66,250 | 91,000 | 289,760 |
| Purchases of property and equipment | 93 | 80 | 360 |
| Net cash provided by (used in) investing activities | 17,448 | 36,425 | 67,342 |
| Issuance of common stock, net of issuance costs-Public Offering | - | 0 | - |
| Issuance of common stock pursuant to exercise of stock options | - | 0 | 0 |
| Return of related party short-swing profits | - | 0 | 215 |
| Repurchase of restricted stock units to satisfy tax withholding | - | 0 | 67 |
| Finance lease liability | 1 | - | - |
| Net cash used in financing activities | -1 | 0 | 148 |
| Net change in cash, cash equivalents and restricted cash | -27,947 | 1,585 | -87,684 |
| Cash, cash equivalents and restricted cash at beginning of period | 78,898 | 77,313 | 164,997 |
| Cash, cash equivalents and restricted cash at end of period | 50,951 | 78,898 | 77,313 |
ROCKET PHARMACEUTICALS, INC. (RCKTW)
ROCKET PHARMACEUTICALS, INC. (RCKTW)